Medtronic Launches Captivia Delivery System

Medtronic has launched Captivia Delivery System for the Valiant Thoracic Stent Graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta.

The system features tip capture for control of the Valiant Thoracic Stent Graft during deployment and a hydrophilic coating applied to the graft cover to facilitate iliac access and delivery through patients’ vasculature.

Reportedly, the new Valiant Captivia system enables physicians to treat a range of anatomies with a stent graft to achieve optimal clinical results. Both the Valiant Thoracic Stent Graft and Captivia Delivery System are approved by the FDA.

The company said that, indicated for the treatment of thoracic aortic lesions, the Valiant Thoracic Stent Graft has emerged as the minimally invasive ‘system of choice’ for thoracic endovascular aortic repair (TEVAR) outside the US.

Giovanni Torsello, chief of vascular surgery at St. Franziskus-Hospital in Muenster, Germany, said: “The Captivia Delivery System’s tip capture feature provides excellent control of the stent graft during deployment, which is critically important when treating lesions in the thoracic aorta, Torsello sIts hydrophilic coating has also made a significant improvement in stent graft delivery. These added features will provide greater confidence in physicians’ ability to treat these very challenging cases.”

Tony Semedo, vice president and general manager of Endovascular Innovations, part of the CardioVascular business at Medtronic, said: Given the widespread acceptance and growing use of our Valiant Thoracic Stent Graft, the Captivia Delivery System represents an enhancement that provides physicians with outstanding ease of access and delivery, as well as deployment accuracy and control. Combined with the Valiant Thoracic Stent Graft, which retains its hallmark attribute of conformability, the new system will expand endovascular treatment to more patients with complex aortic disease.”